FY2028 EPS Estimates for argenx Increased by Leerink Partnrs

argenx SE (NASDAQ:ARGX) – Investment analysts at Leerink Partnrs increased their FY2028 EPS estimates for shares of argenx in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of $34.69 per share for the year, up from their prior forecast of $34.23. The consensus estimate for argenx’s current full-year earnings is $2.78 per share. Leerink Partnrs also issued estimates for argenx’s FY2029 earnings at $41.83 EPS.

A number of other research analysts have also recently weighed in on ARGX. Piper Sandler lifted their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. Citigroup lifted their price target on shares of argenx from $512.00 to $635.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Raymond James reissued a “strong-buy” rating and issued a $605.00 price objective on shares of argenx in a research note on Thursday, October 10th. Truist Financial restated a “buy” rating and set a $700.00 target price (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, JMP Securities increased their price target on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Stock Performance

NASDAQ ARGX opened at $657.97 on Thursday. The business’s fifty day moving average is $636.51 and its 200 day moving average is $574.93. argenx has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The company has a market capitalization of $39.98 billion, a PE ratio of -747.69 and a beta of 0.58.

Institutional Trading of argenx

Hedge funds have recently made changes to their positions in the business. Whipplewood Advisors LLC purchased a new position in argenx in the fourth quarter worth about $37,000. Global Retirement Partners LLC lifted its stake in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after purchasing an additional 61 shares during the period. Venturi Wealth Management LLC purchased a new stake in argenx during the 4th quarter valued at $66,000. Finally, Nkcfo LLC bought a new stake in argenx in the fourth quarter worth $68,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.